Accidental overdose will present no hazard.
Not applicable.
The frequency of adverse reactions documented during clinical trials is given. The frequency is defined as follows: Very Common (> 1/10); Common (>1/100, <1/10); Uncommon (>1/1,000, <1/100); Rare (>1/10,000, <1/1,000); Very Rare (<1/10,000), not known (cannot be estimated from the available data).
Eye disorders:
Common: Eye irritation (including burning and discomfort), eye pain, eye pruritus, visual disturbance.
Postmarketing Experience
The following additional adverse reactions have been identified during postmarketing use of Celluvisc in clinical practice. Because postmarketing reporting of these reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions.
Immune System Disorders:
Hypersensitivity including eye allergy.
Eye Disorders:
Blurred vision, eye discharge, lacrimation increased, ocular hyperemia.
Injury, Poisons and Procedural Complications:
Superficial injury of eye (from the vial tip touching the eye during administration) and/or corneal abrasion.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard.
There are no preclinical data considered relevant to clinical safety beyond data included in other sections of the SPC.
Tear substitute. Treatment of the symptoms of dry eye.
Pharmacotherapeutic group: Other ophthalmologicals
ATC code: S01XA20
Carmellose sodium has no pharmacological effect. Carmellose sodium has a high viscosity resulting in an increased retention time on the eye.
The excipients in Celluvisc were chosen to mimic the electrolyte constitution of tears.
Due to the high molecular weight (approx. 90,000 Daltons) carmellose sodium is unlikely to penetrate the cornea.
If irritation, pain, redness or changes in vision occur or if the patient's condition is worsened treatment discontinuation should be considered and a new assessment made.
Celluvisc may cause transient blurring of vision which may impair the ability to drive or operate machines. The patient should wait until their vision has cleared before driving or using machinery.
Instil 1-2 drops in the affected eye/s 4 times a day or as needed.
Ensure that the single-dose container is intact before use. The eye drop solution should be used immediately after opening.
To avoid contamination or possible eye injury, do not touch tip of the bottle or vial to any surface and avoid contact with the eye.
If Celluvisc is concomitantly used with other ocular eye medications there must be an interval of at least 15 minutes between the two medications (as displacement of a medication may occur).
The eye drops may be used with contact lenses.
Paediatric population
The safety and efficacy of Celluvisc in children and adolescents have been established by clinical experience, but no clinical trial data are available. The posology recommended in adults is recommended in the paediatric population.
Discard any unused solution in opened container i.e. do not re-use container for subsequent doses.
